AM
AMLX.US Amylyx Pharmaceuticals Inc
- Market cap
- USD 3.84B
- P/E
- -
- P/B
- 5.09x
- ROE
- -23.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AMLX.US undervalued?
Graham numberThe Graham number of Amylyx Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amylyx Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Amylyx Pharmaceuticals Inc yet.
Amylyx Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-d…
Full company profileAmylyx Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Amylyx Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.43M | 650K | 285K | 22.2M | 381M | 87.4M | 0.00 | 0.00 |
| Gross Profit | -10.5M | -23.9M | 285K | 19.2M | 355M | 45.2M | -525K | - |
| Operating Income | -13.6M | -39.0M | -82.7M | -201M | 38.8M | -315M | -153M | -186M |
| EBITDA | 1.11M | -39.0M | -82.6M | -201M | 55.4M | -291M | -144M | -173M |
| Net Income | -14.8M | -42.3M | -87.9M | -198M | 49.3M | -302M | -145M | -174M |
| EPS | -0.26 | -0.75 | -1.52 | -2.98 | 0.70 | -4.43 | -1.53 | -1.46 |
| Balance Sheet | ||||||||
| Total Assets | 3.22M | 14.1M | 106M | 391M | 517M | 194M | 333M | 787M |
| Total Liabilities | 28.6M | 80.8M | 257M | 50.8M | 84.0M | 28.9M | 27.4M | 33.1M |
| Shareholders' Equity | -25.4M | -66.7M | -151M | 341M | 433M | 165M | 305M | 754M |
| Cash & Short-term Investments | 3.07M | 12.9M | 96.1M | 347M | 371M | 177M | 317M | 768M |
| Total Debt | 14.9M | 1.43M | - | 6.28M | 4.24M | 1.98M | 5.96M | 4.94M |
| Cash Flow | ||||||||
| Operating Cash Flow | -10.7M | -36.7M | -74.8M | -180M | 11.9M | -168M | -123M | -136M |
| Capital Expenditure | 151K | 151K | 353K | 2.53M | 1.24M | 157K | 138K | 73.3K |
| Free Cash Flow | -10.7M | -36.8M | -75.2M | -182M | 10.7M | -168M | -123M | -136M |
| Ratios | ||||||||
| ROE | - | - | - | -58.2% | 11.4% | -183.1% | -47.4% | -23.0% |
| ROA | -460.1% | -299.8% | -83.2% | -50.7% | 9.5% | -155.8% | -43.5% | -22.1% |
| Net Profit Margin | -1,039.0% | -6,504.6% | -30,834.7% | -892.4% | 12.9% | -345.4% | - | - |
| Debt to Equity | - | - | - | 0.02x | 0.01x | 0.01x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Amylyx Pharmaceuticals Inc dividends
Amylyx Pharmaceuticals Inc has not paid dividends in the last 7 fiscal years.
Who owns Amylyx Pharmaceuticals Inc
- Insiders 6.88%
- Institutions 93.12%
- Public & others 0.00%
- Shares outstanding 129M
- Free float 113M
Top funds holding AMLX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 3.80M | 2.96% | +0.32% | Sep 2026 |
| iShares Russell 2000 ETF | 2.63M | 2.05% | 0.00% | Oct 2026 |
| Fidelity Advisor Biotechnology I | 2.43M | 1.89% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth | 2.12M | 1.65% | 0.00% | Aug 2026 |
| Franklin Biotechnology Discv A(acc)USD | 1.72M | 1.34% | 0.00% | Sep 2026 |
| Strategic Advisers Fidelity US TtlStk | 1.70M | 1.32% | +29.33% | Sep 2026 |
| Fidelity Select Health Care | 1.60M | 1.24% | +12.68% | Aug 2026 |
| Fidelity Stock Selector Small Cap | 1.48M | 1.15% | +17.41% | Aug 2026 |
| Fidelity Select Biotechnology | 1.47M | 1.14% | +33.99% | Aug 2026 |
| Eventide Healthcare & Life Sciences I | 1.32M | 1.03% | -12.39% | Jun 2026 |
| Fidelity Series Small Cap Opps | 1.18M | 0.92% | +17.02% | Aug 2026 |
| Fidelity Small Cap Index | 1.13M | 0.88% | +12.54% | Aug 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 1.08M | 0.84% | +4.18% | Jun 2026 |
| Fidelity Small Cap Growth K6 | 1.05M | 0.82% | 0.00% | Aug 2026 |
| Fidelity Balanced | 981K | 0.76% | +11.60% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 971K | 0.76% | -0.38% | Oct 2026 |
| JPMorgan Mid Cap Growth I | 930K | 0.72% | -1.57% | Sep 2026 |
| Franklin Biotechnology Discovery A | 928K | 0.72% | 0.00% | Sep 2026 |
| T. Rowe Price Health Sciences | 884K | 0.69% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 828K | 0.64% | -0.19% | Oct 2026 |
Top institutions holding AMLX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 16.7M | 13.01% | +0.59% | Jun 2026 |
| BlackRock Inc | 8.83M | 6.87% | -0.02% | Jun 2026 |
| Perceptive Advisors LLC | 8.33M | 6.48% | +0.60% | Jun 2026 |
| TCG Crossover Management, LLC | 6.24M | 4.86% | 0.00% | Jun 2026 |
| COMMODORE CAPITAL LP | 5.65M | 4.39% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 5.24M | 4.07% | 0.00% | Jun 2026 |
| Saturn V Capital Management LLC | 4.62M | 3.60% | +6.30% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.22M | 3.29% | +2.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.13M | 2.44% | +43.91% | Jun 2026 |
| Driehaus Capital Management LLC | 3.04M | 2.36% | +1.67% | Jun 2026 |
| First Light Asset Management, LLC | 3.02M | 2.35% | -5.25% | Jun 2026 |
| Franklin Templeton Inc | 2.95M | 2.29% | +30.45% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.86M | 2.22% | +8.84% | Jun 2026 |
| State Street Corp | 2.60M | 2.03% | +10.16% | Jun 2026 |
| Geode Capital Management, LLC | 2.34M | 1.82% | +5.63% | Jun 2026 |
| Adage Capital Partners Gp LLC | 1.90M | 1.48% | -46.64% | Jun 2026 |
| JPMorgan Chase & Co | 1.86M | 1.45% | +1,067.24% | Jun 2026 |
| Siren, L.L.C. | 1.48M | 1.15% | +20.37% | Jun 2026 |
| Eventide Asset Management, LLC | 1.33M | 1.03% | -12.31% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.06M | 0.83% | +12.36% | Jun 2026 |
Amylyx Pharmaceuticals Inc company profile
- Company name
- Amylyx Pharmaceuticals Inc
- Ticker
- AMLX.US
- Exchange
- USA Stocks
- Listed since
- Jan 7, 2022
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 136
- Fiscal year end
- December
- Address
- 55 Cambridge Parkway, Cambridge, MA, United States, 02142
- Phone
- 617 682 0917
- Website
- amylyx.com
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals Inc management
10- Mr. Joshua B. CohenCo-Founder, Co-CEO & Director · born 1992
- Mr. Justin B. KleeCo-CEO & Director · born 1991
- Mr. James M. Frates M.B.A.Chief Financial Officer · born 1967
- Dr. Camille L. Bedrosian M.D.Chief Medical Officer · born 1953
- Mr. Tom HolmesChief Technical Operations Officer
- Ms. Lindsey AllenHead of Investor Relations & Communications
- Ms. Gina M. Mazzariello J.D.Chief Legal Officer & General Counsel · born 1972
- Ms. Linda A. ArsenaultChief Human Resources Officer
- Ms. Tammy SarnelliGlobal Head of Regulatory Affairs
- Dr. Machelle Manuel Ph.D.VP & Head of Global Medical Affairs